PPARG and metabolic dysfunction-associated steatotic liver disease: Based on previous research and the present findings, the bifunctional pharmacological activities of telmisartan, as an angiotensin II receptor antagonist and PPARγ partial agonist, significantly ameliorate NAFLD activity, alter hepatic fat accumulation, and improve hepatic fibrosis.